Other languages Initiator Pharma A/S

Equities

INIT

DK0060775872

Market Closed - Nasdaq Stockholm Other stock markets 08:59:36 13/05/2024 pm IST			5-day change	1st Jan Change
9.2 ^SEK	0.00%		-2.34%	-0.43%

10/05	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/02	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02
Initiator Pharma Issues New Shares for Debt Conversion	21/02
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	08/01
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	06/23/06
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	19/23/19
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	09/23/09
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	18/23/18
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	05/23/05
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	29/23/29
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	05/23/05
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	06/23/06
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	20/22/20
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/22/04
Initiator Pharma A/S Provides an Update on Its Clinical Programs	04/22/04
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	21/22/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Initiator Pharma A/S

Equities

INIT

DK0060775872

Other languages

Filters